FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000387410> ?p ?o ?g. }

• W2000387410 endingPage "217" @default.
• W2000387410 startingPage "211" @default.
• W2000387410 abstract "This phase I trial was initiated based on encouraging clinical data with 5-fluorouracil (5-FU)/leucovorin (LV), gemcitabine and cisplatin (G-FLIP) in the therapy of solid tumors. In this trial, G-FLIP has been modified to facilitate outpatient administration and to optimize sequence-dependent synergistic activity. Treatment consisted of biweekly (once every 14 days) cycles of sequential gemcitabine 500 mg/m, irinotecan per dose escalation schedule, bolus 5-FU 400 mg/m and LV 300 mg on day 1 followed by a 24-h 5-FU infusion 1500 mg/m, followed by cisplatin 35 mg/m on day 2. The irinotecan starting dose was 80 mg/m and escalated by 20 mg/m in cohorts of three patients until the maximum tolerated dose (MTD) was defined. Twenty-three patients were enrolled (13 men/10 women) with the following cancers: 11 pancreatic, five gallbladder, three squamous cell carcinoma of the head and neck, one hepatocellular carcinoma, one melanoma, one gastric, and one breast cancer. Median patient age was 63 years (range 44-78) and median Karnofsky performance status (KPS) was 80. Patients received a median of 8 cycles (range 1-16) over five irinotecan dose levels (80, 100, 120, 140 and 160 mg/m). Dose-limiting toxicity consisting of grade 3 nausea/vomiting despite aggressive anti-emetic therapy occurred in one patient at dose level 1 and three patients at dose level 3. Grade 3-4 hematological toxicities per patient consisted of thrombocytopenia (3%), anemia (6%), thrombosis (23%), neutropenia (16%) and neutropenic fever (10%). Of 18 patients evaluable for response, one complete response (pancreatic) and eight partial responses (three gallbladder, two pancreatic, two head and neck, and one breast) were attained. Seven patients had disease stabilization (five pancreatic, one hepatocellular and one gastric) for a median of 16 weeks (range 10-22). Median time to disease progression among all 23 patients enrolled to the phase I portion of the trial was 20.5 weeks (range 4-37). We conclude that G-FLIP is a novel outpatient chemotherapy regimen with acceptable toxicity at the maximum tolerated irinotecan dose of 120 mg/m. The phase II trial of G-FLIP using an irinotecan dose of 120 mg/m for patients with metastatic pancreatic cancer is ongoing." @default.
• W2000387410 created "2016-06-24" @default.
• W2000387410 creator A5002758733 @default.
• W2000387410 creator A5010337213 @default.
• W2000387410 creator A5024975908 @default.
• W2000387410 creator A5047450557 @default.
• W2000387410 creator A5074338449 @default.
• W2000387410 creator A5082616695 @default.
• W2000387410 date "2004-03-01" @default.
• W2000387410 modified "2023-09-23" @default.
• W2000387410 title "Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors" @default.
• W2000387410 cites W1959900711 @default.
• W2000387410 cites W1964174069 @default.
• W2000387410 cites W1982885349 @default.
• W2000387410 cites W1994276424 @default.
• W2000387410 cites W2017739390 @default.
• W2000387410 cites W2022315975 @default.
• W2000387410 cites W2116309493 @default.
• W2000387410 cites W2123344367 @default.
• W2000387410 cites W2152864788 @default.
• W2000387410 cites W2155805287 @default.
• W2000387410 cites W2169278727 @default.
• W2000387410 cites W2172761866 @default.
• W2000387410 cites W2188405133 @default.
• W2000387410 cites W222088725 @default.
• W2000387410 cites W2226490553 @default.
• W2000387410 cites W2260154196 @default.
• W2000387410 cites W2323394841 @default.
• W2000387410 cites W2326267475 @default.
• W2000387410 cites W2344721727 @default.
• W2000387410 doi "https://doi.org/10.1097/00001813-200403000-00004" @default.
• W2000387410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15014353" @default.
• W2000387410 hasPublicationYear "2004" @default.
• W2000387410 type Work @default.
• W2000387410 sameAs 2000387410 @default.
• W2000387410 citedByCount "13" @default.
• W2000387410 countsByYear W20003874102012 @default.
• W2000387410 countsByYear W20003874102018 @default.
• W2000387410 countsByYear W20003874102019 @default.
• W2000387410 countsByYear W20003874102021 @default.
• W2000387410 crossrefType "journal-article" @default.
• W2000387410 hasAuthorship W2000387410A5002758733 @default.
• W2000387410 hasAuthorship W2000387410A5010337213 @default.
• W2000387410 hasAuthorship W2000387410A5024975908 @default.
• W2000387410 hasAuthorship W2000387410A5047450557 @default.
• W2000387410 hasAuthorship W2000387410A5074338449 @default.
• W2000387410 hasAuthorship W2000387410A5082616695 @default.
• W2000387410 hasConcept C121608353 @default.
• W2000387410 hasConcept C126322002 @default.
• W2000387410 hasConcept C141071460 @default.
• W2000387410 hasConcept C2776694085 @default.
• W2000387410 hasConcept C2776907518 @default.
• W2000387410 hasConcept C2777063308 @default.
• W2000387410 hasConcept C2780210213 @default.
• W2000387410 hasConcept C2780258809 @default.
• W2000387410 hasConcept C2780259306 @default.
• W2000387410 hasConcept C2780456651 @default.
• W2000387410 hasConcept C2780580376 @default.
• W2000387410 hasConcept C2781413609 @default.
• W2000387410 hasConcept C526805850 @default.
• W2000387410 hasConcept C71924100 @default.
• W2000387410 hasConcept C90924648 @default.
• W2000387410 hasConceptScore W2000387410C121608353 @default.
• W2000387410 hasConceptScore W2000387410C126322002 @default.
• W2000387410 hasConceptScore W2000387410C141071460 @default.
• W2000387410 hasConceptScore W2000387410C2776694085 @default.
• W2000387410 hasConceptScore W2000387410C2776907518 @default.
• W2000387410 hasConceptScore W2000387410C2777063308 @default.
• W2000387410 hasConceptScore W2000387410C2780210213 @default.
• W2000387410 hasConceptScore W2000387410C2780258809 @default.
• W2000387410 hasConceptScore W2000387410C2780259306 @default.
• W2000387410 hasConceptScore W2000387410C2780456651 @default.
• W2000387410 hasConceptScore W2000387410C2780580376 @default.
• W2000387410 hasConceptScore W2000387410C2781413609 @default.
• W2000387410 hasConceptScore W2000387410C526805850 @default.
• W2000387410 hasConceptScore W2000387410C71924100 @default.
• W2000387410 hasConceptScore W2000387410C90924648 @default.
• W2000387410 hasIssue "3" @default.
• W2000387410 hasLocation W20003874101 @default.
• W2000387410 hasLocation W20003874102 @default.
• W2000387410 hasOpenAccess W2000387410 @default.
• W2000387410 hasPrimaryLocation W20003874101 @default.
• W2000387410 hasRelatedWork W1993844652 @default.
• W2000387410 hasRelatedWork W2013902487 @default.
• W2000387410 hasRelatedWork W2078274755 @default.
• W2000387410 hasRelatedWork W2080060706 @default.
• W2000387410 hasRelatedWork W2167562354 @default.
• W2000387410 hasRelatedWork W2276642368 @default.
• W2000387410 hasRelatedWork W2370468903 @default.
• W2000387410 hasRelatedWork W2411380701 @default.
• W2000387410 hasRelatedWork W3088225194 @default.
• W2000387410 hasRelatedWork W4240885285 @default.
• W2000387410 hasVolume "15" @default.
• W2000387410 isParatext "false" @default.
• W2000387410 isRetracted "false" @default.
• W2000387410 magId "2000387410" @default.
• W2000387410 workType "article" @default.